Monograph: |
ABETIMUS (TRADE NAME RIQUENT) IS AN IMMUNOSUPPRESSANT .[1] IT IS A SYNTHETIC BIOLOGICAL CALLED A TOLEROGEN . IT IS MADE OF FOUR DOUBLE-STRANDED OLIGODEOXYRIBONUCLEOTIDES THAT ARE ATTACHED TO A CARRIER PLATFORM AND ARE DESIGNED TO BLOCK SPECIFIC B-CELL ANTI DOUBLE STRANDED DNA ANTIBODIES.[2] IT MAY ALSO COMPLEX ANTI DSDNA ANTIBODIES TOGETHER, THEREFORE DISABLING THEM. THIS WAY ABETIMUS WAS SUPPOSED TO HELP TREAT SYSTEMIC LUPUS ERYTHEMATOSUS AND SPECIFICALLY LUPUS NEPHRITIS .
IT WAS DEVELOPED BY LA JOLLA PHARMACEUTICAL , WHO APPLIED FOR MARKETING AUTHORISATIONS IN THE MID-2000S, BUT THE DRUG WAS NEVER MARKETED IN THE US OR IN EUROP
|